Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors - brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry.
Martina KojanovaJan HugoBarbora VelackovaPetra CetkovskaJorga FialovaTomas DolezalMartin TichySpyridon Gkalpakiotisnull nullPublished in: The Journal of dermatological treatment (2022)
This real-life study demonstrated the effectiveness and good safety profile of all currently available IL-17 inhibitors.